did fda ban semaglutide the Compounded and Tirzepatide? The FDA Just Banned Compounded

Wu, H., Jones, R

Neither has been studied specifically in fibromyalgia

A new finding from Phase 3 is dysesthesia (abnormal touch sensation) in up to 20.9% at the 12 mg dose

Bottom line: MeAgain is the daily GLP-1 tracker and companion

HSA/FSA Considerations Pre-Tax Savings: Using HSA/FSA Funds: Compounded tirzepatide is HSA/FSA eligible Consultations are eligible Supplies are eligible Effectively 20-30% discount (depending on tax bracket) Cost After Tax Savings: $349/month at 25% tax bracket: Effective cost: ~$262/month Annual savings: $1,044 $349/month at 30% tax bracket: Effective cost: ~$244/month Annual savings: $1,257 Makes already affordable treatment even more accessible

Regarding exenatide, Trevaskis et al